Globus Medical (GMED)
Globus Medical on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus.
8.2M
Short interest
settlement 2026-10-15
5.5
Days to cover
+0.3 days vs prior
53.5%
Short share of volume
2026-11-03
1,791
Fails to deliver
settlement 2026-10-14
Thu 5 Nov
Next earnings
estimated date
-$4.4M
Insider flow, 90 days
0 buys, 2 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in GMED is 8,189,831 shares, up 1,422,319 shares over the last month. Over the last 48 readings it ranged from 2,180,970 shares (31 January 2025) to 8,437,114 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 1.5M shares a day that is 5.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/gmed" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 8,189,831 | -2.9% | 1,497,115 | 5.47 |
| 2026-09-30 | 8,437,114 | +24.7% | 1,640,932 | 5.14 |
| 2026-09-15 | 6,767,512 | +2.2% | 1,469,890 | 4.60 |
| 2026-08-31 | 6,620,718 | -2.7% | 1,013,754 | 6.53 |
| 2026-08-14 | 6,802,529 | -1.2% | 1,721,196 | 3.95 |
| 2026-07-31 | 6,886,644 | -2.6% | 1,409,379 | 4.89 |
| 2026-07-15 | 7,069,160 | -4.6% | 2,018,657 | 3.50 |
| 2026-06-30 | 7,409,990 | +35.5% | 2,079,068 | 3.56 |
| 2026-06-15 | 5,469,519 | +39.6% | 1,595,502 | 3.43 |
| 2026-05-29 | 3,916,683 | +14.7% | 2,027,320 | 1.93 |
| 2026-05-15 | 3,414,228 | +9.4% | 2,111,683 | 1.62 |
| 2026-04-30 | 3,120,512 | -5.8% | 885,553 | 3.52 |
| 2026-04-15 | 3,313,920 | +17.1% | 1,142,106 | 2.90 |
| 2026-03-31 | 2,831,226 | -14.1% | 991,496 | 2.86 |
| 2026-03-13 | 3,293,919 | +0.7% | 990,473 | 3.33 |
| 2026-02-27 | 3,270,517 | -30.1% | 1,421,356 | 2.30 |
| 2026-02-13 | 4,675,619 | +13.4% | 1,186,125 | 3.94 |
| 2026-01-30 | 4,124,408 | +6.4% | 1,101,849 | 3.74 |
| 2026-01-15 | 3,875,375 | -9.1% | 2,036,599 | 1.90 |
| 2025-12-31 | 4,262,628 | +4.0% | 1,179,628 | 3.61 |
| 2025-12-15 | 4,097,040 | -6.8% | 1,523,562 | 2.69 |
| 2025-11-28 | 4,397,222 | -8.9% | 1,722,060 | 2.55 |
| 2025-11-14 | 4,824,835 | -32.5% | 3,245,321 | 1.49 |
| 2025-10-31 | 7,150,376 | +12.9% | 1,252,412 | 5.71 |
| 2025-10-15 | 6,331,670 | +3.5% | 1,330,805 | 4.76 |
| 2025-09-30 | 6,116,115 | -7.1% | 1,575,243 | 3.88 |
| 2025-09-15 | 6,585,764 | +14.3% | 1,023,814 | 6.43 |
| 2025-08-29 | 5,760,326 | +5.8% | 954,539 | 6.03 |
| 2025-08-15 | 5,442,884 | +13.8% | 1,776,115 | 3.06 |
| 2025-07-31 | 4,783,494 | +5.9% | 1,569,313 | 3.05 |
| 2025-07-15 | 4,516,423 | +4.7% | 1,752,445 | 2.58 |
| 2025-06-30 | 4,312,022 | -7.1% | 1,246,985 | 3.46 |
| 2025-06-13 | 4,640,087 | -10.1% | 962,232 | 4.82 |
| 2025-05-30 | 5,163,596 | +14.5% | 1,709,218 | 3.02 |
| 2025-05-15 | 4,509,326 | +7.0% | 2,548,699 | 1.77 |
| 2025-04-30 | 4,215,167 | -0.6% | 845,543 | 4.99 |
| 2025-04-15 | 4,240,127 | +28.4% | 1,352,751 | 3.13 |
| 2025-03-31 | 3,301,258 | +36.2% | 1,299,760 | 2.54 |
| 2025-03-14 | 2,423,670 | -7.5% | 1,440,759 | 1.68 |
| 2025-02-28 | 2,621,722 | +13.0% | 1,429,480 | 1.83 |
| 2025-02-14 | 2,319,546 | +6.3% | 1,351,514 | 1.72 |
| 2025-01-31 | 2,180,970 | -12.8% | 1,139,623 | 1.91 |
| 2025-01-15 | 2,501,338 | +0.5% | 1,350,769 | 1.85 |
| 2024-12-31 | 2,489,401 | +4.5% | 930,232 | 2.68 |
| 2024-12-13 | 2,382,852 | -2.4% | 753,790 | 3.16 |
| 2024-11-29 | 2,442,199 | -12.4% | 910,019 | 2.68 |
| 2024-11-15 | 2,788,105 | -2.4% | 1,407,667 | 1.98 |
| 2024-10-31 | 2,856,269 | +0.7% | 719,727 | 3.97 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of GMED volume is 53.5%, down 22.1 points over the last five sessions. Over the last 30 readings it ranged from 52.2% (28 October 2026) to 86.6% (1 October 2026). The latest reading sits at the bottom of that range. The latest reading is 16.9 points below the 30-session average of 70.4%, on 617K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 330K | 617K | 53.5% | 993 |
| 2026-11-02 | 389K | 629K | 61.9% | 52 |
| 2026-10-30 | 463K | 666K | 69.5% | 98 |
| 2026-10-29 | 272K | 369K | 73.5% | 670 |
| 2026-10-28 | 174K | 334K | 52.2% | 554 |
| 2026-10-27 | 201K | 266K | 75.6% | 756 |
| 2026-10-26 | 323K | 430K | 75.1% | 557 |
| 2026-10-23 | 274K | 347K | 79.0% | 531 |
| 2026-10-22 | 402K | 538K | 74.8% | 1,594 |
| 2026-10-21 | 285K | 380K | 75.1% | 471 |
| 2026-10-20 | 417K | 763K | 54.7% | 1,197 |
| 2026-10-19 | 321K | 549K | 58.4% | 291 |
| 2026-10-16 | 625K | 1.0M | 60.9% | 1,611 |
| 2026-10-15 | 539K | 905K | 59.5% | 158 |
| 2026-10-14 | 267K | 340K | 78.4% | 74 |
| 2026-10-13 | 257K | 356K | 72.3% | 545 |
| 2026-10-12 | 369K | 503K | 73.3% | 2,034 |
| 2026-10-09 | 278K | 372K | 74.8% | 144 |
| 2026-10-08 | 383K | 619K | 61.8% | 1,355 |
| 2026-10-07 | 791K | 1.1M | 73.9% | 1,123 |
| 2026-10-06 | 485K | 588K | 82.5% | 102 |
| 2026-10-05 | 464K | 656K | 70.8% | 549 |
| 2026-10-02 | 404K | 542K | 74.5% | 936 |
| 2026-10-01 | 502K | 580K | 86.6% | 96 |
| 2026-09-30 | 308K | 416K | 73.9% | 1,271 |
| 2026-09-29 | 388K | 540K | 71.8% | 517 |
| 2026-09-28 | 384K | 610K | 62.9% | 2,787 |
| 2026-09-25 | 408K | 543K | 75.1% | 205 |
| 2026-09-24 | 371K | 513K | 72.2% | 2,322 |
| 2026-09-23 | 351K | 419K | 83.7% | 974 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in GMED is 1,791 shares, down 2,557 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (6 May 2026) to 3,792,906 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 1,791 | $76.32 | $137K |
| 2026-10-07 | 4,348 | $76.43 | $332K |
| 2026-10-05 | 1,328 | $75.60 | $100K |
| 2026-09-11 | 65,524 | $73.56 | $4.8M |
| 2026-09-10 | 66,330 | $74.52 | $4.9M |
| 2026-09-02 | 37 | $80.48 | $3K |
| 2026-08-31 | 2 | $82.97 | $166 |
| 2026-08-28 | 3 | $82.54 | $248 |
| 2026-08-24 | 15,609 | $86.91 | $1.4M |
| 2026-08-19 | 100 | $86.44 | $9K |
| 2026-08-12 | 4,696 | $85.15 | $400K |
| 2026-08-10 | 5,287 | $82.35 | $435K |
| 2026-08-07 | 30,568 | $81.08 | $2.5M |
| 2026-08-05 | 9,975 | $81.51 | $813K |
| 2026-08-04 | 4,572 | $81.46 | $372K |
| 2026-08-03 | 9,635 | $78.79 | $759K |
| 2026-07-29 | 48 | $80.58 | $4K |
| 2026-07-28 | 4 | $78.25 | $313 |
| 2026-07-08 | 2,826 | $78.83 | $223K |
| 2026-07-07 | 20,170 | $80.50 | $1.6M |
| 2026-07-06 | 6,364 | $80.12 | $510K |
| 2026-07-01 | 97 | $79.01 | $8K |
| 2026-06-30 | 3,516 | $83.94 | $295K |
| 2026-06-29 | 3,792,906 | $86.25 | $327.1M |
| 2026-05-29 | 14,597 | $82.45 | $1.2M |
| 2026-05-26 | 1,245 | $84.81 | $106K |
| 2026-05-19 | 1,383 | $78.93 | $109K |
| 2026-05-06 | 1 | $90.03 | $90 |
| 2026-04-16 | 11,109 | $94.55 | $1.1M |
| 2026-04-06 | 243 | $87.92 | $21K |
Insider trades
SEC Form 4, newest first. JSONInsiders at GMED reported 2 open-market sells worth $4.4M in the last 90 days and no open-market buys. Latest filing: TOBIN JAMES R (Director) on 2026-09-15.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | TOBIN JAMES R | Director | Exercise or conversion | 15K | $63.68 | $955K | 30K |
| 2026-09-15 | TOBIN JAMES R | Director | Sell | 30K | $74.58 | $2.2M | 0 |
| 2026-09-15 | TOBIN JAMES R | Director | Exercise or conversion | 15K | $53.75 | $806K | 15K |
| 2026-08-18 | ZARRILLI STEPHEN T | Director | Sell | 25K | $87.04 | $2.2M | 0 |
| 2026-08-18 | ZARRILLI STEPHEN T | Director | Exercise or conversion | 25K | $53.27 | $1.3M | 25K |
| 2026-07-27 | Davidar David D | Director | Gift | 3K | $0.00 | $0 | 508K |
| 2026-06-05 | Davidar David D | Director | Sell | 25K | $80.76 | $2.0M | 510K |
| 2026-06-05 | Davidar David D | Director | Exercise or conversion | 25K | $26.27 | $657K | 535K |
| 2026-06-04 | RHOADS ANN D | Director | Exercise or conversion | 25K | $26.27 | $657K | 40K |
| 2026-02-25 | Huller Kelly | EVP, GC, Corporate Secretary | Sell | 20K | $94.50 | $1.9M | 0 |
| 2026-02-25 | Huller Kelly | EVP, GC, Corporate Secretary | Exercise or conversion | 20K | $43.58 | $872K | 20K |
| 2026-02-12 | Huller Kelly | EVP, GC, Corporate Secretary | Sell | 10K | $87.67 | $877K | 0 |
| 2026-02-12 | Huller Kelly | EVP, GC, Corporate Secretary | Exercise or conversion | 10K | $45.64 | $456K | 10K |
| 2026-01-08 | Kline Kyle | Senior Vice President, CFO | Sell | 4K | $101.10 | $363K | 0 |
| 2026-01-08 | Kline Kyle | Senior Vice President, CFO | Exercise or conversion | 4K | $51.87 | $186K | 4K |
| 2026-01-08 | Norwalk Leslie V | Director | Sell | 2K | $101.10 | $202K | 10K |
| 2025-12-12 | Norwalk Leslie V | Director | Sell | 4K | $88.85 | $355K | 12K |
| 2025-12-08 | Paul David C | Executive Chairman | Exercise or conversion | 34K | $25.52 | $877K | 60K |
| 2025-12-01 | Kline Kyle | Senior Vice President, CFO | Exercise or conversion | 5K | $64.44 | $322K | 14K |
| 2025-12-01 | Kline Kyle | Senior Vice President, CFO | Sell | 19K | $90.00 | $1.7M | 0 |
| 2025-12-01 | Kline Kyle | Senior Vice President, CFO | Exercise or conversion | 5K | $63.68 | $312K | 19K |
| 2025-12-01 | Kline Kyle | Senior Vice President, CFO | Exercise or conversion | 5K | $56.43 | $282K | 9K |
| 2025-12-01 | Kline Kyle | Senior Vice President, CFO | Exercise or conversion | 4K | $53.14 | $194K | 4K |
| 2025-11-25 | Huller Kelly | SVP, GC, Corporate Secretary | Sell | 8K | $90.00 | $675K | 0 |
| 2025-11-25 | Huller Kelly | SVP, GC, Corporate Secretary | Exercise or conversion | 8K | $25.96 | $195K | 8K |
| 2025-11-12 | Davidar David D | Director | Sell | 25K | $86.00 | $2.2M | 516K |
| 2025-11-12 | Davidar David D | Director | Exercise or conversion | 25K | $25.52 | $638K | 541K |
| 2025-11-11 | ZARRILLI STEPHEN T | Director | Sell | 25K | $84.29 | $2.1M | 0 |
| 2025-11-11 | ZARRILLI STEPHEN T | Director | Exercise or conversion | 25K | $44.14 | $1.1M | 25K |
| 2025-11-10 | RHOADS ANN D | Director | Sell | 2K | $85.00 | $170K | 15K |
| 2025-11-07 | RHOADS ANN D | Director | Sell | 8K | $81.00 | $648K | 17K |
| 2025-09-15 | RHOADS ANN D | Director | Sell | 10K | $58.46 | $585K | 25K |
| 2025-02-28 | RHOADS ANN D | Director | Sell | 8K | $78.68 | $590K | 35K |
| 2025-01-10 | Pfeil Keith W | COO, CFO | Exercise or conversion | 6K | $49.65 | $290K | 6K |
| 2025-01-10 | Pfeil Keith W | COO, CFO | Sell | 13K | $88.17 | $1.1M | 2K |
| 2025-01-10 | Pfeil Keith W | COO, CFO | Sell | 2K | $89.17 | $149K | 0 |
| 2025-01-10 | Pfeil Keith W | COO, CFO | Exercise or conversion | 8K | $53.27 | $444K | 14K |
| 2025-01-02 | Davidar David D | Director | Gift | 6K | $0.00 | $0 | 510K |
| 2024-12-02 | Huller Kelly | SVP, GC, Corporate Secretary | Exercise or conversion | 3K | $24.21 | $61K | 3K |
| 2024-12-02 | Huller Kelly | SVP, GC, Corporate Secretary | Sell | 3K | $87.00 | $218K | 0 |
| 2024-11-22 | Lemaitre Dan | Director | Exercise or conversion | 1K | $65.05 | $71K | 1K |
| 2024-11-22 | Lemaitre Dan | Director | Sell | 1K | $85.02 | $93K | 0 |
| 2024-11-22 | Davidar David D | Director | Sell | 7K | $85.00 | $575K | 516K |
| 2024-11-22 | Davidar David D | Director | Sell | 7K | $85.00 | $573K | 166K |
| 2024-11-21 | Scavilla Daniel T | President, CEO | Sell | 130K | $85.00 | $11.1M | 0 |
| 2024-11-21 | Scavilla Daniel T | President, CEO | Exercise or conversion | 80K | $43.58 | $3.5M | 130K |
| 2024-11-21 | Scavilla Daniel T | President, CEO | Exercise or conversion | 50K | $43.77 | $2.2M | 50K |
| 2024-11-21 | Lemaitre Dan | Director | Sell | 13K | $85.00 | $1.1M | 0 |
| 2024-11-21 | Lemaitre Dan | Director | Exercise or conversion | 13K | $65.05 | $864K | 13K |
| 2024-11-21 | Davidar David D | Director | Sell | 13K | $85.00 | $1.1M | 523K |
| 2024-11-21 | Davidar David D | Director | Sell | 13K | $85.00 | $1.1M | 173K |
| 2024-11-15 | Paul David C | Executive Chairman | Exercise or conversion | 26K | $24.10 | $628K | 26K |
| 2024-11-06 | Scavilla Daniel T | President, CEO | Exercise or conversion | 30K | $26.27 | $788K | 30K |
| 2024-11-06 | Huller Kelly | SVP, GC, Corporate Secretary | Sell | 3K | $80.02 | $200K | 3K |
| 2024-11-06 | Scavilla Daniel T | President, CEO | Exercise or conversion | 30K | $43.77 | $1.3M | 60K |
| 2024-11-06 | Scavilla Daniel T | President, CEO | Sell | 60K | $80.02 | $4.8M | 0 |
| 2024-11-06 | Huller Kelly | SVP, GC, Corporate Secretary | Exercise or conversion | 5K | $24.21 | $121K | 5K |
| 2024-11-06 | Huller Kelly | SVP, GC, Corporate Secretary | Sell | 3K | $82.00 | $205K | 0 |
| 2024-10-16 | Davidar David D | Director | Sell | 30K | $75.04 | $2.3M | 536K |
| 2024-10-16 | Davidar David D | Director | Sell | 20K | $75.03 | $1.5M | 186K |
| 2024-10-16 | Huller Kelly | SVP, GC, Corporate Secretary | Sell | 8K | $75.02 | $563K | n/a |
| 2024-10-16 | Huller Kelly | SVP, GC, Corporate Secretary | Exercise or conversion | 8K | $25.80 | $194K | 8K |
| 2024-09-13 | Davidar David D | Director | Sell | 25K | $70.46 | $1.8M | 566K |
| 2024-09-13 | Davidar David D | Director | Exercise or conversion | 25K | $25.52 | $638K | 591K |
| 2024-09-13 | RHOADS ANN D | Director | Exercise or conversion | 20K | $25.52 | $510K | 58K |
| 2024-09-13 | RHOADS ANN D | Director | Exercise or conversion | 15K | $24.10 | $362K | 38K |
| 2024-09-13 | RHOADS ANN D | Director | Sell | 15K | $70.36 | $1.1M | 43K |
| 2024-07-11 | Norwalk Leslie V | Director | Sell | 1K | $70.00 | $70K | 16K |
| 2024-05-10 | Lemaitre Dan | Director | Exercise or conversion | 18K | $53.27 | $932K | 63K |
| 2024-05-10 | Lemaitre Dan | Director | Exercise or conversion | 18K | $43.77 | $766K | 28K |
| 2024-05-10 | Lemaitre Dan | Director | Sell | 63K | $64.61 | $4.1M | 0 |
| 2024-05-10 | Lemaitre Dan | Director | Exercise or conversion | 18K | $43.58 | $763K | 46K |
| 2024-05-08 | Davidar David D | Director | Sell | 20K | $65.00 | $1.3M | 566K |
| 2024-03-15 | Norwalk Leslie V | Director | Sell | 11K | $51.99 | $551K | 17K |
| 2024-03-01 | Huller Kelly | SVP, GC, Corporate Secretary | Sell | 4K | $53.79 | $236K | 3K |
| 2024-03-01 | Huller Kelly | SVP, GC, Corporate Secretary | Exercise or conversion | 8K | $24.90 | $187K | 8K |
| 2024-03-01 | Huller Kelly | SVP, GC, Corporate Secretary | Sell | 3K | $54.53 | $170K | 0 |
| 2024-01-18 | Davidar David D | Director | Gift | 8K | $0.00 | $0 | 586K |
| 2023-09-01 | DeFord John A | Director | Grant | 16K | price not stated in the filing | not stated | 16K |
| 2023-09-01 | Norwalk Leslie V | Director | Grant | 2K | price not stated in the filing | not stated | 2K |
| 2023-09-01 | Norwalk Leslie V | Director | Grant | 26K | price not stated in the filing | not stated | 28K |
| 2023-09-01 | Wolterman Dan | Director | Grant | 24K | price not stated in the filing | not stated | 24K |
| 2023-09-01 | DeFord John A | Director | Grant | 16K | price not stated in the filing | not stated | 16K |
| 2023-05-15 | Lemaitre Dan | Director | Exercise or conversion | 1K | $23.95 | $35K | 12K |
| 2023-05-15 | Lemaitre Dan | Director | Exercise or conversion | 11K | $24.10 | $253K | 23K |
| 2023-05-15 | Lemaitre Dan | Director | Exercise or conversion | 14K | $25.52 | $357K | 37K |
| 2023-05-15 | Lemaitre Dan | Director | Sell | 43K | $56.98 | $2.5M | 11K |
| 2023-05-15 | Lemaitre Dan | Director | Exercise or conversion | 18K | $26.27 | $460K | 54K |
| 2023-02-09 | Lemaitre Dan | Director | Exercise or conversion | 6K | $23.95 | $133K | 11K |
| 2023-02-02 | Pfeil Keith W | SVP, Chief Financial Officer | Sell | 29K | $77.57 | $2.3M | 0 |
| 2023-02-02 | Pfeil Keith W | SVP, Chief Financial Officer | Exercise or conversion | 15K | $53.27 | $799K | 29K |
| 2023-02-02 | Pfeil Keith W | SVP, Chief Financial Officer | Exercise or conversion | 14K | $49.65 | $703K | 14K |
| 2023-01-27 | Lemaitre Dan | Director | Exercise or conversion | 5K | $12.59 | $66K | 5K |
| 2023-01-27 | RHOADS ANN D | Director | Exercise or conversion | 8K | $12.59 | $94K | 23K |
| 2022-12-01 | Huller Kelly | SVP, GC, Corporate Secretary | Exercise or conversion | 8K | $12.59 | $94K | 8K |
| 2022-12-01 | Huller Kelly | SVP, GC, Corporate Secretary | Sell | 8K | $75.00 | $563K | 0 |
| 2022-04-19 | Davidar David D | Director | Sell | 32K | $78.03 | $2.5M | 601K |
| 2022-04-08 | Huller Kelly | SVP, GC, Corporate Secretary | Exercise or conversion | 3K | $15.34 | $38K | 3K |
| 2022-04-08 | Huller Kelly | SVP, GC, Corporate Secretary | Sell | 3K | $75.59 | $189K | 0 |
| 2022-03-15 | TOBIN JAMES R | Director | Sell | 9K | $65.47 | $579K | 0 |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON16 Form 144 notices on file for GMED worth $20.9M at the prices reported; 2 in the last 90 days worth $4.4M. Latest: TOBIN JAMES R filed on 2026-09-15 to sell 30,000 shares ($2.2M) from 2026-09-15.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-15 | TOBIN JAMES RDirector | 30K | $2.2M | 0.022% | 2026-09-15 | Raymond James & Associates Inc. |
| 2026-08-18 | ZARRILLI STEPHEN TDirector | 25K | $2.2M | 0.019% | 2026-08-18 | Raymond James & Associates, Inc. |
| 2026-06-05 | Davidar David DDirector | 25K | $2.0M | 0.018% | 2026-06-05 | Raymond James & Associates |
| 2026-04-14 | DeFord John AFormer Director | 30K | $2.8M | 0.022% | 2026-04-14 | Raymond James & Associates |
| 2026-02-25 | Huller KellyOfficer | 20K | $1.9M | 0.015% | 2026-02-25 | Raymond James & Associates |
| 2026-02-12 | Huller KellyOfficer | 10K | $876K | 0.007% | 2026-02-12 | Raymond James & Associates |
| 2026-01-08 | Kline KyleOfficer | 4K | $363K | 0.003% | 2026-01-08 | RAYMOND JAMES & ASSOCIATES |
| 2026-01-08 | Norwalk Leslie VDirector | 2K | $202K | 0.001% | 2026-01-08 | Raymond James & Associates |
| 2025-12-12 | Norwalk Leslie VDirector | 4K | $355K | 0.003% | 2025-12-12 | Raymond James & Associates |
| 2025-12-01 | Kline KyleOfficer | 19K | $1.7M | 0.014% | 2025-12-01 | Raymond James & Associates |
| 2025-11-25 | Huller KellyOfficer | 8K | $675K | 0.006% | 2025-11-25 | Raymond James & Associates |
| 2025-11-12 | ZARRILLI STEPHEN TDirector | 25K | $2.1M | 0.019% | 2025-11-11 | Raymond James & Associates |
| 2025-11-12 | Davidar David DDirector | 25K | $2.1M | 0.019% | 2025-11-12 | Raymond James & Associates |
| 2025-11-10 | RHOADS ANN DDirector | 2K | $170K | 0.001% | 2025-11-10 | Raymond James & Associates |
| 2025-11-07 | RHOADS ANN DDirector | 8K | $648K | 0.006% | 2025-11-07 | Raymond James & Associates |
| 2025-09-15 | RHOADS ANN DDirector | 10K | $584K | 0.010% | 2025-09-15 | Raymond James & Associates |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of GMED in its latest filing, on Schedule 13G (passive). The holder is BlackRock, Inc. at 8.0% of the class (10,704,283 shares), filed 2026-10-27 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-30 | 13G/Ano. 1 | Vanguard Capital Managementinvestment adviser | 6.0M | 4.4% | 2026-09-30 |
| 2026-10-27 | 13G/Ano. 15 | BlackRock, Inc.parent holding company | 10.7M | 8.0% | 2026-09-30 |
| 2026-03-26 | 13G/Ano. 13 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding GMED at their latest 13F. JSON5 of the 30 tracked managers held GMED at their latest 13F, $49.2M in total at quarter-end prices. Bridgewater Associates is the largest at $27.8M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Bridgewater Associates | 2026-06-30 | 352K | $27.8M | 0.11% | +22K |
| Renaissance Technologies | 2026-06-30 | 197K | $15.6M | 0.02% | new |
| AQR Capital Management | 2026-06-30 | 37K | $2.9M | 0.00% | -810K |
| Millennium Management | 2026-06-30 | 29K | $2.3M | 0.00% | -1.6M |
| D. E. Shaw & Co. | 2026-06-30 | 8K | $656K | 0.00% | -20K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Globus Medical reported revenue of $789.6M, up 5.9% from the same quarter a year earlier, and net income of $151.6M (1.10 diluted EPS). In FY 2025 it generated $753.4M of operating cash flow and spent $300.5M on buybacks.
- Cash
- $507.7M
- Equity
- $4.77B
- Total assets
- $5.49B
- Shares outstanding
- 134,261,914
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $789.6M | $151.6M | 19.2% | 1.10 |
| Q1 FY 2026 | 2026-03-31 | $759.9M | $124.3M | 16.4% | 0.90 |
| Q4 FY 2025derived | 2025-12-31 | $826.4M | $140.6M | 17.0% | n/a |
| Q3 FY 2025 | 2025-09-30 | $769.0M | $119.0M | 15.5% | 0.88 |
| Q2 FY 2025 | 2025-06-30 | $745.3M | $202.8M | 27.2% | 1.49 |
| Q1 FY 2025 | 2025-03-31 | $598.1M | $75.5M | 12.6% | 0.54 |
| Q4 FY 2024derived | 2024-12-31 | $657.3M | $26.5M | 4.0% | n/a |
| Q3 FY 2024 | 2024-09-30 | $625.7M | $51.8M | 8.3% | 0.38 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2.94B | $537.9M | $753.4M | $164.7M | $300.5M | n/a |
| FY 2024 | 2024-12-31 | $2.52B | $103.0M | $520.6M | $115.4M | $85.8M | n/a |
| FY 2023 | 2023-12-31 | $1.57B | $122.9M | $243.5M | $78.3M | $225.6M | n/a |
| FY 2022 | 2022-12-31 | $1.02B | $190.2M | $178.5M | $74.0M | $144.5M | n/a |
| FY 2021 | 2021-12-31 | $958.1M | $149.2M | $276.3M | $56.9M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-04 from the cover page.
What this page is
Globus Medical in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Globus Medical (GMED), SEC CIK 1237831, listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-15.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-30.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-15.JSON and CSV
- Company record
- EDGAR filing index for CIK 1237831Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
Other company pages
Datasets
Frequently Asked Questions
How much of GMED is sold short?
8,189,831 shares were held short at the 2026-10-15 settlement, 5.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is GMED's daily short volume?
On 2026-11-03, 329,852 of the 616,855 GMED shares reported to FINRA were sold short, 53.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does GMED have fails to deliver?
The SEC's latest file shows 1,791 GMED shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are GMED insiders buying or selling?
Insiders at GMED reported 2 open-market sells worth $4.4M in the last 90 days and no open-market buys. Latest filing: TOBIN JAMES R (Director) on 2026-09-15.
Have GMED insiders filed to sell?
16 Form 144 notices on file for GMED worth $20.9M at the prices reported; 2 in the last 90 days worth $4.4M. Latest: TOBIN JAMES R filed on 2026-09-15 to sell 30,000 shares ($2.2M) from 2026-09-15.
Who owns 5% or more of GMED?
1 holder reports 5% or more of GMED in its latest filing, on Schedule 13G (passive). The holder is BlackRock, Inc. at 8.0% of the class (10,704,283 shares), filed 2026-10-27 for an event on 2026-09-30.
What did GMED report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Globus Medical reported revenue of $789.6M, up 5.9% from the same quarter a year earlier, and net income of $151.6M (1.10 diluted EPS). In FY 2025 it generated $753.4M of operating cash flow and spent $300.5M on buybacks.
Which tracked 13F managers own GMED?
5 of the 30 tracked 13F managers held GMED shares at their latest filing, $49.2M in all. The largest: Ray Dalio's Bridgewater Associates (352K shares, $27.8M), Renaissance Technologies (197K shares, $15.6M), Cliff Asness's AQR Capital Management (37K shares, $2.9M), Izzy Englander's Millennium Management (29K shares, $2.3M), D. E. Shaw & Co. (8K shares, $656K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.